Breaking News Instant updates and real-time market news.

AMGN

Amgen

$185.48

1.79 (0.97%)

, MYL

Mylan

$38.48

-0.36 (-0.93%)

17:15
06/04/18
06/04
17:15
06/04/18
17:15

FDA approves first biosimilar to Neulasta

The U.S. Food and Drug Administration today approved Fulphila, pegfilgrastim-jmdb, as the first biosimilar to Neulasta to decrease the chance of infection as suggested by febrile neutropeniafever, often with other signs of infection, associated with an abnormally low number of infection-fighting white blood cells, in patients with non-myeloid cancer who are receiving myelosuppressive chemotherapy that has a clinically significant incidence of febrile neutropenia.The FDA granted approval of Fulphila to Mylan GmbH (MYL). Neulasta is made by Amgen (AMGN).

AMGN

Amgen

$185.48

1.79 (0.97%)

MYL

Mylan

$38.48

-0.36 (-0.93%)

  • 04

    Jun

  • 13

    Nov

AMGN Amgen
$185.48

1.79 (0.97%)

05/17/18
PIPR
05/17/18
NO CHANGE
Target $190
PIPR
Overweight
Amgen's Aimovig launch in migraine should beat expectations, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond kept his Overweight rating and $190 price target on Amgen (AMGN) after today's FDA approval of Aimovig in migraine. The analyst notes that this marks the first anti-CGRP therapy approval in what is expected to be a crowded space, adding that Amgen and its partner Novartis (NVS) have "effectively capitalized on their first-mover advantage." The analyst says the smart pricing for the product should allow this launch to "beat expectations".
05/18/18
WELS
05/18/18
NO CHANGE
WELS
Amgen migraine drug price may be below expectations, says Wells Fargo
The FDA, as expected, approved Amgen (AMGN) and Novartis' (NVS) first-in-class anti-CGRP treatment Aimovig for the prevention of migraine, Wells Fargo analyst David Maris tells investors in a research note. The only part of the news which may be somewhat unexpected could be the pricing, which came in at $575 per month or $6,900 annually, the analyst adds. He thinks some investors may have been expecting the price in the $12,000 range. Maris thinks there may be a potential negative read-through on the pricing for Teva (TEVA) and to a lesser extent, Allergan (AGN).
05/18/18
CANT
05/18/18
NO CHANGE
Target $18
CANT
Neutral
Amgen approval in migraine positive for Teva, says Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen thinks FDA approval of Amgen's (AMGN) Aimovig is positive for Teva (TEVA) as well as other new potential migraine treatments coming to the market because it underscores the large unmet need. She notes, however, that Teva does not expect approval until later this year given its manufacturing issues. The analyst keeps a Neutral rating on Teva with an $18 price target.
05/18/18
JEFF
05/18/18
NO CHANGE
Target $200
JEFF
Buy
Amgen price for Aimovig lower than expected, says Jefferies
Jefferies analyst Michael Yee says the confirmed list price of $6,900 for Amgen's (AMGN) Aimovig is lower than Street expectations of $7,000-$10,000. The analyst thinks the net price could fall to around $5,000-$6,000 as Allergan's (AGN) Botox is around $6,000. Amgen's pricing strategy sends a good message and fits well into the current reimbursement environment, Yee tells investors in a research note. He keeps a Buy rating on the shares with a $200 price target.
MYL Mylan
$38.48

-0.36 (-0.93%)

04/25/18
WELS
04/25/18
NO CHANGE
WELS
Market Perform
Glaxo comments on Advair have negative read through for Mylan, says Wells Fargo
Noting that GlaxoSmithKline (GSK) said it now expects branded Advair sales to decline 30% this year, even excluding the impact of a generic, Wells Fargo analyst David Maris said the news has a negative read through for Mylan (MYL) given that its generic Advair is one of the company's highest profile pipeline items. While Advair will be a good generic opportunity, it represents "a fraction of what some might have previously believed," said Maris, who has a Market Perform rating on Mylan shares.
05/15/18
MZHO
05/15/18
UPGRADE
Target $27
MZHO
Buy
Mizuho compares Valeant portfolio to Mylan in upgrade to Buy
Mizuho analyst Irina Koffler upgraded Valeant Pharmaceuticals (VRX) to Buy from Neutral and raised her price target for the shares to $27 from $15. The stock closed yesterday down 4c to $20.81. Adjusting individual product growth estimates has made the analyst more constructive on Valeant's turnaround story. The company's portfolio now looks Mylan-like (MYL) in that 70% of revenue consists of stable products that are either consumer-focused, or older drugs that are already generic, Koffler tells investors in a research note. Further, the analyst sees growth potential from Valeant's pipeline, which she notes contains multiple catalysts in 2018-2020 and is not in her estimates. She thinks that in order for the stock to work over the next year, Valeant just needs to execute on its quarters and push through new product launches.
05/18/18
BERN
05/18/18
NO CHANGE
Target $54
BERN
Outperform
Biocon 483 letter won't delay approval of Mylan's Neulasta, says Bernstein
Bernstein analyst Aaron Gal said that the 483 letter for Biocon's Bangalore facility contains seven observations, all related to cleaning procedures, and does not contain any argument of systemic or recurring problem, suggestions of any of the procedure deviations creating patient risk or problems requiring changes in the facility structure or equipment. In a research note to investors, Gal said the 483 is viewed as being on the "lighter side," and can be "reasonably" addressed through change in procedure, and does not believe it will delay the tentative approval of Biocon/Mylan's Neulasta. The analyst has an Outperform rating and $54 price target on Mylan.
05/23/18
JPMS
05/23/18
NO CHANGE
Target $53
JPMS
Overweight
Mylan risk/reward favorable into June catalysts, says JPMorgan
JPMorgan analyst Chris Schott sees a favorable setup and risk/reward for Mylan shares heading into June. His downside case, in which biosimilar Neulasta, generic Advair and generic Restasis do not get approved in 2018, supports earnings per share in the low $5 range and a stock that he struggles to see sustainably below the mid $30's. The analyst's upside case, which has some mix of Advair, Neulasta and Restasis approved, supports a share price "well above" $50. Looking beyond near-term catalysts, Schott believes Mylan is "very well-positioned" within the generics space. He keeps an Overweight rating on the shares with a $53 price target.

TODAY'S FREE FLY STORIES

02:45
10/23/18
10/23
02:45
10/23/18
02:45
General news
FX Update: Both the Dollar and Yen have outperformed »

FX Update: Both the…

01:45
10/23/18
10/23
01:45
10/23/18
01:45
General news
Asian Market Wrap: »

Asian Market Wrap:…

XOM

Exxon Mobil

$81.15

-0.83 (-1.01%)

20:43
10/22/18
10/22
20:43
10/22/18
20:43
Initiation
Exxon Mobil initiated at Simmons »

Exxon Mobil assumed with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VZ

Verizon

$54.96

0.07 (0.13%)

, MCD

McDonald's

$166.53

-0.92 (-0.55%)

20:25
10/22/18
10/22
20:25
10/22/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

VZ

Verizon

$54.96

0.07 (0.13%)

MCD

McDonald's

$166.53

-0.92 (-0.55%)

MM

Millennial Media

$0.00

(0.00%)

UTX

United Technologies

$126.42

-2.22 (-1.73%)

LMT

Lockheed Martin

$326.45

-1.77 (-0.54%)

NEE

NextEra Energy

$172.71

-0.76 (-0.44%)

CAT

Caterpillar

$128.64

-2.73 (-2.08%)

BIIB

Biogen

$315.67

-4.18 (-1.31%)

CNC

Centene

$141.34

-1.565 (-1.10%)

GLW

Corning

$30.83

0.06 (0.19%)

PCAR

Paccar

$60.51

0.25 (0.41%)

RF

Regions Financial

$16.39

-0.5 (-2.96%)

FITB

Fifth Third

$25.38

-0.95 (-3.61%)

HBAN

Huntington Bancshares

$13.66

-0.54 (-3.80%)

TRU

TransUnion

$68.59

0.39 (0.57%)

XRX

Xerox

$26.39

-0.47 (-1.75%)

HOG

Harley-Davidson

$38.72

-0.84 (-2.12%)

JBLU

JetBlue

$16.57

0.04 (0.24%)

GPK

Graphic Packaging

$12.31

-0.4 (-3.15%)

SLCA

U.S. Silica

$15.65

-0.41 (-2.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 01

    Nov

  • 06

    Nov

  • 08

    Nov

  • 11

    Nov

  • 11

    Nov

  • 12

    Nov

  • 13

    Nov

  • 26

    Nov

  • 13

    Dec

  • 14

    Dec

TOT

Total

$59.85

-0.95 (-1.56%)

20:22
10/22/18
10/22
20:22
10/22/18
20:22
Initiation
Total initiated at Simmons »

Total assumed with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RDS.A

Royal Dutch Shell

$64.88

-0.66 (-1.01%)

20:17
10/22/18
10/22
20:17
10/22/18
20:17
Initiation
Royal Dutch Shell initiated at Simmons »

Royal Dutch Shell assumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQNR

Equinor

$26.39

-0.6 (-2.22%)

20:13
10/22/18
10/22
20:13
10/22/18
20:13
Initiation
Equinor initiated at Simmons »

Equinor assumed with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVX

Chevron

$117.23

-0.82 (-0.69%)

20:11
10/22/18
10/22
20:11
10/22/18
20:11
Initiation
Chevron initiated at Simmons »

Chevron assumed with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

COP

ConocoPhillips

$72.06

-0.43 (-0.59%)

20:06
10/22/18
10/22
20:06
10/22/18
20:06
Initiation
ConocoPhillips initiated at Simmons »

ConocoPhillips assumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

BP

BP

$43.15

-0.84 (-1.91%)

20:02
10/22/18
10/22
20:02
10/22/18
20:02
Initiation
BP initiated at Simmons »

BP assumed with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WRE

Washington REIT

$27.97

-0.305 (-1.08%)

, AAPL

Apple

$220.62

1.34 (0.61%)

19:51
10/22/18
10/22
19:51
10/22/18
19:51
Upgrade
Washington REIT, Apple, Amazon.com rating change at Stifel »

Washington REIT upgraded…

WRE

Washington REIT

$27.97

-0.305 (-1.08%)

AAPL

Apple

$220.62

1.34 (0.61%)

AMZN

Amazon.com

$1,789.00

25.09 (1.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 26

    Oct

JBGS

JBG Smith Properties

$36.81

0.005 (0.01%)

, AAPL

Apple

$220.62

1.34 (0.61%)

19:47
10/22/18
10/22
19:47
10/22/18
19:47
Upgrade
JBG Smith Properties, Apple, Amazon.com rating change at Stifel »

JBG Smith Properties…

JBGS

JBG Smith Properties

$36.81

0.005 (0.01%)

AAPL

Apple

$220.62

1.34 (0.61%)

AMZN

Amazon.com

$1,789.00

25.09 (1.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

ARNC

Arconic

$21.45

-0.45 (-2.05%)

, APO

Apollo Global

$29.47

-0.02 (-0.07%)

19:38
10/22/18
10/22
19:38
10/22/18
19:38
Periodicals
Arconic Board evaluating $11B Apollo Global offer, Reuters reports »

Arconic is said to have…

ARNC

Arconic

$21.45

-0.45 (-2.05%)

APO

Apollo Global

$29.47

-0.02 (-0.07%)

BX

Blackstone

$34.38

-0.28 (-0.81%)

CG

Carlyle Group

$20.46

0.29 (1.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 31

    Oct

ARNC

Arconic

$21.45

-0.45 (-2.05%)

, APO

Apollo Global

$29.47

-0.02 (-0.07%)

19:34
10/22/18
10/22
19:34
10/22/18
19:34
Periodicals
Breaking Periodicals news story on Arconic, Apollo Global »

Arconic to consider $11B…

ARNC

Arconic

$21.45

-0.45 (-2.05%)

APO

Apollo Global

$29.47

-0.02 (-0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 31

    Oct

ENLK

EnLink Midstream Partners

$18.10

-0.19 (-1.04%)

19:25
10/22/18
10/22
19:25
10/22/18
19:25
Upgrade
EnLink Midstream Partners rating change at Credit Suisse »

EnLink Midstream Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

HLX

Helix Energy

$10.28

0.03 (0.29%)

19:25
10/22/18
10/22
19:25
10/22/18
19:25
Hot Stocks
Helix Energy reports Q3 adjusted EBITDA $58.6M vs. $30.5M last year »

CEO Owen Kratz says:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 14

    Nov

  • 15

    Nov

HLX

Helix Energy

$10.28

0.03 (0.29%)

19:24
10/22/18
10/22
19:24
10/22/18
19:24
Earnings
Helix Energy reports Q3 adjusted EPS 18c, consensus 11c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 14

    Nov

  • 15

    Nov

UAL

United Continental

$88.62

1.19 (1.36%)

19:13
10/22/18
10/22
19:13
10/22/18
19:13
Periodicals
United CEO upbeat in memo to workers on Q3, SVBJ reports »

In an internal memo to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

I

Intelsat

$34.98

0.385 (1.11%)

, EUTLF

Eutelsat Communications

$0.00

(0.00%)

19:11
10/22/18
10/22
19:11
10/22/18
19:11
Hot Stocks
Intelsat, SES, Eutelsat in transition on planning to support 5G deployment »

The C-Band Alliance,…

I

Intelsat

$34.98

0.385 (1.11%)

EUTLF

Eutelsat Communications

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

CDNS

Cadence Design

$40.62

0.49 (1.22%)

, SSNC

SS&C

$49.91

-0.37 (-0.74%)

19:05
10/22/18
10/22
19:05
10/22/18
19:05
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

CDNS

Cadence Design

$40.62

0.49 (1.22%)

SSNC

SS&C

$49.91

-0.37 (-0.74%)

FRBA

First Bank

$12.42

0.015 (0.12%)

ZION

Zions Bancorp

$45.33

-1.64 (-3.49%)

RNST

Renasant

$35.44

-1.1 (-3.01%)

CR

Crane

$87.33

-0.28 (-0.32%)

BRO

Brown & Brown

$29.12

0.27 (0.94%)

CEMI

Chembio Diagnostics

$9.68

-0.05 (-0.51%)

RH

RH

$109.10

-13.485 (-11.00%)

MC

Moelis

$50.66

-0.21 (-0.41%)

AMTD

TD Ameritrade

$49.89

-0.6 (-1.19%)

AFMD

Affimed N.V.

$3.15

-0.06 (-1.87%)

PTI

Proteostasis

$7.17

-0.77 (-9.70%)

EIGR

Eiger BioPharmaceuticals

$10.65

-1.2 (-10.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 31

    Oct

  • 02

    Nov

  • 14

    Nov

  • 15

    Nov

  • 15

    Nov

  • 27

    Nov

  • 05

    Dec

  • 06

    Dec

  • 06

    Dec

  • 12

    Mar

  • 23

    Oct

  • 24

    Oct

DIS

Disney

$118.22

-0.59 (-0.50%)

18:55
10/22/18
10/22
18:55
10/22/18
18:55
Periodicals
Disney spends $20M to support Florida's Amendment 3, Bloomberg says »

Disney and the Seminole…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

HSBC

HSBC

$40.36

-0.095 (-0.23%)

18:50
10/22/18
10/22
18:50
10/22/18
18:50
Periodicals
HSBC teams up with Avant to offer personal loans, Bloomberg says »

HSBC Holdings is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WSFS

WSFS Financial

$43.08

-0.46 (-1.06%)

18:49
10/22/18
10/22
18:49
10/22/18
18:49
Earnings
WSFS Financial reports Q3 EPS 96c, consensus 92c »

Reports Q3 NII $63.1M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

IQV

Iqvia

$126.36

-0.52 (-0.41%)

, CRM

Salesforce

$142.92

2.47 (1.76%)

18:22
10/22/18
10/22
18:22
10/22/18
18:22
Recommendations
Iqvia, Salesforce analyst commentary at Piper Jaffray »

Iqvia price target raised…

IQV

Iqvia

$126.36

-0.52 (-0.41%)

CRM

Salesforce

$142.92

2.47 (1.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 06

    Dec

  • 03

    Mar

BK

BNY Mellon

$46.47

-0.94 (-1.98%)

18:20
10/22/18
10/22
18:20
10/22/18
18:20
Hot Stocks
BNY Mellon, Bank of the West reach pact on new real-time payments solution »

BNY Mellon and Bank of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.